Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Signant Health extends eCOA leadership position through operational innovations that reduce timelines by at least one-third

Published

on

signant-health-extends-ecoa-leadership-position-through-operational-innovations-that-reduce-timelines-by-at-least-one-third

PHILADELPHIA, May 8, 2024 /PRNewswire/ — Signant Health, the leader in evidence generation for modern clinical trials, announced today that it has substantially reduced implementation timelines for its flagship eCOA solution, TrialMax®. By leveraging process and technology enhancements, Signant’s operational teams can reduce the time it takes to go live with electronic patient-reported outcomes solutions by thirty percent or more.  

Sponsors and Contract Research Organizations (CROs) have relied on Signant’s eCOA solution for over 20 years. The solution is known for its flexibility, reliability, scientific support, global logistics support, and ability to scale to any size trial, anywhere in the world. Traditionally, the time to bring the system live for patients and sites was commensurate with the operational complexity and trial design.  
According to the company, customers can now benefit from this highly customizable eCOA solution along with Signant’s leading levels of science, scale, and service – delivered under much faster timelines.
“We are excited to offer customers the best of both worlds,” said Sanjiv Waghmare, Signant’s chief product officer. “They can get the fully featured, market-leading eCOA solution they already use and love, at a much faster pace. We believe this is especially meaningful as trial designs continue to increase in complexity. We want to ensure our customers hit their FPFV dates and start collecting high quality data without worrying about if their eCOA solution will be available.”    
According to Waghmare, Signant’s engineering and operational teams identified areas where process enhancements and automation could dramatically reduce common implementation steps regardless of trial complexity. These steps cover all aspects of a typical eCOA timeline including study build, testing, translations, scale management, and validation.
“This is just the beginning of our efforts to deliver complexity at speed, with outstanding quality,” continued Waghmare. “We are also bringing additional efficiencies to our processes that will accelerate post-implementation support, including reporting, analytics, and data change management.”
Signant also offers a tenured solution for eCOA studies as part of its Signant SmartSignals® Unified Platform, which is fully integrated with EDC, RTSM, eConsent, and telemedicine. For more information about all Signant’s eClinical solutions, go to www.signanthealth.com.
About Signant Health
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
Contact: 
Heather [email protected]+1 610.400.4141
Logo – https://mma.prnewswire.com/media/1202052/Signant_Health_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/signant-health-extends-ecoa-leadership-position-through-operational-innovations-that-reduce-timelines-by-at-least-one-third-302138773.html

Continue Reading
Advertisement
Stake.com

Artificial Intelligence

SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care

Published

on

sophia-genetics-launches-global-consortium,-sophia-unity,-to-accelerate-cancer-research,-drug-development,-and-data-driven-patient-care

New collective intelligence network to enable the most advanced research in oncology in support of precision medicine
BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.

To advance the adoption of precision oncology, it is crucial to have access to large-scale data from a wide range of modalities (such as imaging, genomics, pathology and clinical notes), and diverse set of patient profiles. Currently, no single institution globally collects the necessary volume and diversity of information to propel the healthcare field forward. SOPHiA GENETICS has launched SOPHiA UNITY to answer that need and meet the demand for high-quality, diverse data at scale, aiming to drive a new era of precision oncology research.
The collective intelligence network will advance research initiatives using SOPHiA CarePath™, the multimodal module on the SOPHiA DDM™ Platform, to aggregate and analyze complex real-world data. This data will be harmonized and curated using SOPHiA GENETICS’ advanced AI-based technology and proprietary algorithms. Through SOPHiA GENETICS’ unique platform and CarePath™ offering, SOPHiA UNITY members will have access to meaningful, data-driven insights that will support decision-making and expedite oncology research.
“At SOPHiA GENETICS, we have mastered the challenge of harmonizing and connecting genomic data and have the capabilities to do the same with other modalities through our CarePath™ module,” said Jurgi Camblong, PhD., Co-founder and CEO of SOPHiA GENETICS. “SOPHiA UNITY will usher in the next era of precision medicine innovation by bringing together best-in-class institutions that are committed to the advancement of oncology research and the use of data-driven medicine. We are extremely optimistic about the insights this collective intelligence network will generate to further our shared goal.”
SOPHiA GENETICS announced that the first member to join SOPHiA UNITY is Memorial Sloan Kettering Cancer Center, a top cancer treatment and research institution and world leader in patient care, research, and educational programs. Additional members will be announced in the coming months.
“I am looking forward to participating in the new data-driven consortium and partnering with other institutions to draw deeper insights from our collective data,” said Mrinal Gounder, M.D., Sarcoma Oncologist & Early Drug Development Specialist and Physician Ambassador to India and Asia, Memorial Sloan Kettering Cancer Center.
Leading academic cancer centers who are looking to connect with like-minded researchers globally are eligible to join the SOPHiA UNITY collective intelligence network and gather insights that can be implemented locally. For more information, visit SOPHiAGENETICS.COM, or connect on LinkedIn. 
About SOPHiA GENETICSSOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. 
SOPHiA GENETICS Forward-Looking Statements:  This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 
Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.
Logo – https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/sophia-genetics-launches-global-consortium-sophia-unity-to-accelerate-cancer-research-drug-development-and-data-driven-patient-care-302159702.html

Continue Reading

Artificial Intelligence

Global Energy Prize 2024 shortlist announced

Published

on

global-energy-prize-2024-shortlist-announced

MONTEVIDEO, Uruguay, May 30, 2024 /PRNewswire/ — The shortlist of the Global Energy Prize 2024 includes 15 scientists from twelve countries and territories: Belarus, China, Hong Kong (China), Japan, the Republic of Cyprus, Russia, Saudi Arabia, Singapore, Switzerland, the United Kingdom and the United States.

“The wide geography of shortlisted applications underlines the international status of the Prize, which is a recognized benchmark for research and development in the field of energy. Due to the wide variety and depth of topics presented, the International Committee will have the opportunity to select the best of the best,” said Rae Kwon Chung, Nobel laureate, Chairman of the International Committee of the Global Energy Prize.
The laureates of the Global Energy Prize 2024 will be chosen during a closed meeting of the International Award Committee to be held in July.
The shortlist of the Global Energy Prize 2024 includes:
Conventional Energy
1. Zi-Qiang Zhu, UKHead of the Electrical Machines and Drives Research Group, University of Sheffield
2. Fei Duan, SingaporeAssociate Professor, School of Mechanical and Aerospace Engineering, Nanyang Technological University
3. Leonard Vasiliev, BelarusHead of the Porous Media Laboratory, A.V. Lykov Heat&Mass Transfer Institute of the National Academy of Sciences of Belarus
4. Abdulaziz Al-Qasim, Saudi ArabiaHead of Upstream Hydrogen Technology and Sustainability, Saudi Aramco
5. Alexander Mikhalevich, BelarusDirector, Institute of Energy Problems of the National Academy of Sciences of Belarus
Non-Conventional Energy
1. Héctor D. Abruña, USAEmile Chamot Professor of Chemistry, Cornell University
2. Issa Batarseh, USAPegasus Professor, Director of the Florida Power Electronics Center, University of Central Florida
3. Soteris Kalogirou, Republic of CyprusProfessor, Cyprus University of Technology
4. Jinyue Jerry Yan, Hong Kong (China)Chair Professor of Energy and Buildings, Hong Kong Polytechnic University
5. Hongxing Yang, Hong Kong (China)Professor, Hong Kong Polytechnic University
New Ways of Energy Application
1. Amit Goyal, USAFounding Director, RENEW Institute, State University of New York at Buffalo
2. Mohammad Nazeeruddin, SwitzerlandProfessor Emeritus, Swiss Federal Institute of Technology Lausanne
3. Minggao Ouyang, ChinaProfessor, Tsinghua University
4. Garri Popov, RussiaProfessor, Director, Research Institute of Applied Mechanics and Electrodynamics, Moscow Aviation Institute
5. Kouki Matsuse, JapanEmeritus Professor, Meiji University

View original content:https://www.prnewswire.co.uk/news-releases/global-energy-prize-2024-shortlist-announced-302159675.html

Continue Reading

Artificial Intelligence

AI-Driven Advertising to Surge from $370B in 2022 to $1.3T by 2032

Published

on

ai-driven-advertising-to-surge-from-$370b-in-2022-to-$1.3t-by-2032

USA News Group News CommentaryIssued on behalf of Scope AI Corp.
VANCOUVER, BC, May 30, 2024 /PRNewswire/ — USA News Group News Commentary – The use of artificial intelligence is on the rise, with the advertising and marketing sector gaining some of the most benefits. Analysts are already projecting major gains, with Statista projecting advertising spending enabled by AI amounted to a respectable $370 billion in 2022, but will rise significantly to $1.3 trillion by 2032. According to analysts at McKinsey & Company who are projecting generative AI (gen AI) could add $4.4 trillion annually to the global economy. Several tech companies have recently enhanced the integration of AI in marketing, offering swift, secure, and cost-effective solutions for businesses to adopt AI technology in advertising over the past week, including: Scope AI Corp. (CSE: SCPE) (OTCQB: SCPCF), Meta Platforms, Inc. (NASDAQ: META), Veritone, Inc. (NASDAQ: VERI), Alphabet Inc. (NASDAQ: GOOG, GOOGL), and Adobe Inc. (NASDAQ: ADBE).

The article continued: Seeing the extraordinary speed of AI’s advancements and impacts, combined with surging private- and public-sector demand, is causing regulators in the USA and EU to issue legislation calling for action. Now analysts are trying to determine whether the GenAI boom is setting up to be another bubble, or a legitimate long-term investment opportunity.
SCOPE AI ENGAGES WITH AD AGENCIES AND NETWORKS TO OPTIMIZE GEM PLATFORM
Scope AI Corp. (CSE: SCPE) (OTCQB: SCPCF) (FSE: VN8) (“Scope” or the “Company”) today announced its collaboration with several leading ad agencies and ad networks. This initiative aims to gain insights into the primary challenges these organizations face in analyzing the efficacy of different ad creatives and page layouts, as well as the difficulties and costs associated with testing.
These friendly collaborations are part of Scope AI’s commitment to ensuring that the functionality and features of its GEM (General Enterprise Machine Learning) platform are the best market-product fit. By engaging directly with industry professionals, Scope AI is gathering critical feedback to refine and enhance GEM’s capabilities, making it a more valuable tool for advertisers, brands, agencies, and Adtech service providers.
GEM, Scope AI’s flagship product, is designed to revolutionize the advertising technology sector through advanced AI-driven visual recognition and neural network technology. The platform will enable users to streamline processes, maximize return on ad spend, and analyze user behavior through custom neural networks without the need for expensive and risky live campaign testing.
“Our approach is to start with the pain points of our potential users and build solutions based on those insights,” said James Young, CEO of Scope AI Corp. “We believe in understanding the real-world challenges faced by our partners, rather than falling into the common software trap of ‘build it and they will come.’ This collaboration ensures that GEM is not just another tool, but a solution that addresses the specific needs of the advertising community.”
Scope AI’s commitment to innovation and user-centric development is further evidenced by its expanding development team, which is focused on incorporating feedback from these collaborations into the GEM platform. By doing so, Scope AI aims to deliver cutting-edge AI solutions that drive growth, productivity, and campaign performance in the advertising technology sector.
CONTINUED… Read this and more news for Scope AI at:  https://usanewsgroup.com/2024/04/26/the-currency-of-tomorrow-why-investing-in-cutting-edge-ai-recognition-tech-could-mean-big-money/
In other industry developments and happenings in the market this week include:
Meta Platforms, Inc. (NASDAQ: META), the parent company of Facebook, Instagram, and WhatsApp, recently said it had found “likely AI-generated” content used deceptively on its Facebook and Instagram platforms. In its latest quarterly security report, the social media company reported that certain accounts were masquerading as Jewish students, African Americans, and other concerned groups, targeting audiences primarily in the United States and Canada. These activities were linked to STOIC, a political marketing firm based in Tel Aviv.
“With the issues with AI, we’re concerned with Meta’s inability to evaluate, particularly advertising and paid content related to the elections,” said Christina O’Connell, manager of shareholder engagement at Ekō, a corporate accountability organization representing Meta’s retail shareholders. 
In a statement, Meta said its commitment to responsible AI principles, board oversight, efforts to tackle misinformation and disinformation, and the creation of watermarking tools enhance transparency regarding the impact of its products.
“AI tools help us identify and remove content that violates our policies, in some cases even before users report it to us,” said Meta in the statement. “We have also built one of the largest independent fact-checking networks of any platform, with more than 90 partners around the world to review and rate viral misinformation in more than 60 languages.”
Veritone, Inc. (NASDAQ: VERI), a designer of human-centered AI solutions serving customers in talent acquisition, was recently tapped by talent agency Creative Artists Agency (CAA) as a tech partner to build and operate an early-stage database housing replicas of its clients’ digital likenesses. Dubbed ‘The CAA Vault’, the in-house service was launched in September 2023 to scan, capture, and securely store clients’ digital likenesses (face and body) and voice, with the intent to give talent ownership, control and permission over their digital identities to address issues of consent, credit, and compensation related to AI usage.
CAA and Veritone are boasting that their collaboration is an example of “the power of ethical AI” that showcases the “importance of fostering responsible practices within the entertainment industry.”
“Ethics-led and talent-friendly applications of emerging technologies, like AI, are a top priority for CAA, driving us to innovate new ways to support and protect artists,” said Alexandra Shannon, head of strategic development at CAA. “The launch of The CAA Vault is one such innovation. By partnering with a trusted organization like Veritone, we can maintain the security of the artist’s assets, while working to ensure that AI is responsibly integrated into opportunities across the entertainment landscape.”
As per the deal, CAA is accessing Veritone’s Digital Media Hub technology to store the intellectual property for participating talent, with Veritone ingesting, organizing and storing the digital assets and all associated metadata, like synthetic counterparts, including digital scans and voice recordings.
Alphabet Inc. (NASDAQ: GOOG, GOOGL), parent company to Google and YouTube, recently stated a press roundtable ahead of Google’s Marketing Live event, that advertisers will get prominent placement for the platforms’ generative AI search features. AI Overviews will incorporate ads above, below, and within AI-generated search results, according to Rachel Melgaard, Google’s Director of Global Search.
“We’ve been testing this for a while now and we’ve actually found that people find these ads really helpful and advertisers can find these ads effective,” said Melgaard. With these updates, Google bolstered its already massive search advertisement business improving its generative-AI powered search results, and building up on the more than $46 billion in revenue the company made last quarter.
This followed upon when Google introduced a suite of ad products powered by generative AI, tools that could produce instant copy and images, in mid-2023.
Adobe Inc. (NASDAQ: ADBE), a global leader in digital media and marketing solutions, recently announced the new Adobe Express for Enterprise, built to empower businesses to accelerate marketing content creation and extend easy, on-brand content production to communications, sales and other business users.
“With the exponential growth in demand for personalized experiences, companies must find new ways to supercharge the production of content that connects with customers and elevates their brands,” said Govind Balakrishnan, senior vice president, Adobe Express Product Group and Creative Cloud Services at Adobe. “Adobe Express for Enterprise is the only solution that brings together enterprise-grade brand management, intuitive tools, advanced AI designed to be safe for business and seamless workflows with world-class creative apps – empowering individuals across the enterprise to produce more impactful, on-brand content faster than ever before.”
Article Source: https://usanewsgroup.com/2024/04/26/the-currency-of-tomorrow-why-investing-in-cutting-edge-ai-recognition-tech-could-mean-big-money/ 
CONTACT:USA NEWS [email protected](604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Scope AI Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares Scope AI Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Scope AI Corp. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Scope AI Corp. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/ai-driven-advertising-to-surge-from-370b-in-2022-to-1-3t-by-2032–302159602.html

Continue Reading
Advertisement
Stake.com
Advertisement

Latest News

Trending